Methodology breakdown computing — it will appear here on its own.
Structure Therapeutics Inc - ADR (GPCR) is currently considered not halal (non-compliant), per our secondary compliance provider (last assessed 2026-08-12). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computing the full ratio and business-activity breakdown for GPCR — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 27.50 | BUY |
| Stochastic %K (14) | 2.20 | BUY |
| CCI (20) | -187.32 | BUY |
| Williams %R (14) | -97.80 | BUY |
| MACD (12,26,9) | -1.11 | SELL |
| ROC (10) | -19.86 | SELL |
| Momentum (10) | -9.80 | SELL |
| EMA (10) | 44.66 | SELL |
| SMA (10) | 45.33 | SELL |
| EMA (20) | 46.92 | SELL |
| SMA (20) | 48.59 | SELL |
| EMA (30) | 47.83 | SELL |
| SMA (30) | 49.45 | SELL |
| EMA (50) | 48.30 | SELL |
| SMA (50) | 50.01 | SELL |
| EMA (100) | 48.38 | SELL |
| SMA (100) | 46.05 | SELL |
| EMA (200) | 49.34 | SELL |
| SMA (200) | 54.45 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Background via Yahoo Finance — informational, not part of the verdict.
Weak — low conviction, small size or skip
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 43 |
| ⏰ 4H | BEARISH | 39 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | RANGING | 234 |
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
